Recordati announces new three-year plan
Italian pharma major Recordati (RECI: MI) has set new three-year financial targets for the period 2025-2027, aiming for fiscal year (FY) 2027 revenues of 3.0–3.2 billion euros ($4.1-$4.4 billion) and earnings before interest, tax, depreciation and amortization (EBITDA) of 1.14–1.225 billion euros, driven by a balanced strategy of organic growth, rare disease leadership, and targeted M&A.
The group will also continue to pursue targeted pipeline opportunities, investing behind lower-risk lifecycle management programs for new indications and geographic expansion, while sustaining sector-leading margins.
Recordati’s Rare Diseases (RD) business continues to be a major growth engine, forecast to deliver 17–20% CAGR (2024–2027), underpinned by expanded indications like Isturisa (osilodrostat) in the USA and a reinforced pipeline of lower-risk, high-value opportunities.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze